Mustang Bio Inc
NASDAQ:MBIO
Mustang Bio Inc
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. The company is headquartered in New York City, New York and currently employs 102 full-time employees. The company went IPO on 2017-08-22. The firm's pipeline is focused on three core areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. Its products include MB-107 and MB-207 is an Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency (XSCID). XSCID is a rare genetic immune system condition also known as bubble boy disease. The company is developing CAR T therapies for hematologic malignancies in partnership with COH targeting CD123 (MB-102) and CS1 (MB-104) and with Fred Hutch targeting CD20 (MB-106). The firm is also developing CAR T therapies for solid tumors in partnership with COH targeting IL13Ra2 (MB-101), HER2 (MB-103) and PSCA (MB-105).
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. The company is headquartered in New York City, New York and currently employs 102 full-time employees. The company went IPO on 2017-08-22. The firm's pipeline is focused on three core areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. Its products include MB-107 and MB-207 is an Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency (XSCID). XSCID is a rare genetic immune system condition also known as bubble boy disease. The company is developing CAR T therapies for hematologic malignancies in partnership with COH targeting CD123 (MB-102) and CS1 (MB-104) and with Fred Hutch targeting CD20 (MB-106). The firm is also developing CAR T therapies for solid tumors in partnership with COH targeting IL13Ra2 (MB-101), HER2 (MB-103) and PSCA (MB-105).
